子宫内膜异位症切除术后预防子宫内膜瘤复发的维持治疗:系统评价与网状Meta分析
该系统评价与网状Meta分析检索MEDLINE、COCHRANE和Embase至2021年4月30日,纳入11项研究共2394例育龄期子宫内膜异位症行卵巢囊肿剔除或病灶切除的患者,比较术后辅助治疗与维持激素干预对子宫内膜瘤复发的影响。结果显示,与期待管理相比,GnRHa联合DNG(OR 0.04,95%CI 0.01-0.27)可能最有效,而单用GnRHa(OR 0.47,95%CI 0.12-1.89)与对照无显著差异。
要点
- 与期待管理相比,GnRHa联合DNG的OR为0.04(95%CI 0.01-0.27),SUCRA=94.0。
- 单用GnRHa的OR为0.47(95%CI 0.12-1.89),SUCRA=17.3,与对照无显著差异。
- 作者认为GnRHa联合DNG维持治疗可能最有效,仍需大规模RCT。
核心结论
- 在网状Meta分析中,术后联合辅助治疗及较长维持激素治疗优于单药预防子宫内膜瘤复发,GnRHa联合DNG维持治疗可能最有效,仍需大规模RCT。
研究设计与样本
- 系统评价与网状Meta分析,检索MEDLINE、COCHRANE和Embase自建库至2021年4月30日。
- 纳入随机对照试验或队列研究,对象为育龄期子宫内膜异位症行卵巢囊肿剔除或子宫内膜异位病灶切除的患者。
- 共纳入11项研究,其中2项为RCT、9项为队列研究,合计2394例患者。
- 干预包括术后辅助治疗(GnRHa)及术后维持激素干预超过1年(OCPs、DNG、LNGIUS),对照为期待管理。
- 6种干预组1665例(69.6%),期待管理组729例(30.4%)。
主要发现
- 与期待管理相比,GnRHa联合DNG的OR为0.04(95%CI 0.01-0.27),SUCRA=94.0。
- 与期待管理相比,DNG的OR为0.11(95%CI 0.04-0.32),SUCRA=69.7。
- 与期待管理相比,GnRHa联合OCP的OR为0.12(95%CI 0.02-0.64),SUCRA=63.4。
- 与期待管理相比,GnRHa联合LNGIUS的OR为0.13(95%CI 0.03-0.66),SUCRA=59.4。
- 与期待管理相比,OCP的OR为0.21(95%CI 0.13-0.36),SUCRA=43.6;单用GnRHa的OR为0.47(95%CI 0.12-1.89),SUCRA=17.3,与对照无显著差异。
关键数值与推荐
- GnRHa联合DNG与期待管理比较:OR 0.04(95%CI 0.01-0.27),SUCRA=94.0。
- DNG与期待管理比较:OR 0.11(95%CI 0.04-0.32),SUCRA=69.7。
- GnRHa联合OCP与期待管理比较:OR 0.12(95%CI 0.02-0.64),SUCRA=63.4。
- GnRHa联合LNGIUS与期待管理比较:OR 0.13(95%CI 0.03-0.66),SUCRA=59.4。
- OCP与期待管理比较:OR 0.21(95%CI 0.13-0.36),SUCRA=43.6;GnRHa与期待管理比较:OR 0.47(95%CI 0.12-1.89),SUCRA=17.3,无显著差异。
临床怎么用
- 作者认为,术后联合辅助治疗及较长维持激素治疗可能优于单药用于预防子宫内膜瘤复发。
- 作者认为,GnRHa联合DNG维持治疗可能最有效。
- 作者指出,仍需大规模RCT验证上述药物。
局限性
- 作者指出仍需大规模RCT验证上述药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of different hormone therapies in preventing postoperative endometrioma recurrence. DATA SOURCES: The MEDLINE, COCHRANE, and Embase electronic databases were searched from inception to 30 April 2021. METHODS OF STUDY SELECTION: Randomized controlled trials (RCTs) or cohort studies including reproductive age women with endometriosis undergoing ovarian cystectomy or excision of endometriotic lesions compared the effects of postoperative adjuvant therapy (gonadotropin-releasing hormone agonist [GnRHa]) and postoperative maintenance hormone interventions for more than 1 year (i.e., oral contraceptive pills [OCPs], dienogest [DNG], levonorgestrel-releasing intrauterine system [LNGIUS]) on endometrioma recurrence. TABULATION, INTEGRATION, AND RESULTS: Data collection and analysis of the data were independently performed 2 two reviewers. A total of 11 studies were included, of which 2 were RCTs, and 9 were cohort studies. There were 2394 patients with 6 interventions (cases: 1665, 69.6%) and expectant management (cases: 729, 30.4%). Relative treatment effects were estimated using network meta-analysis and ranked in descending order. The clinical effectiveness of these drugs (vs expectant management) was as follows: GnRHa plus DNG (odds ratio [OR], 0.04; 95% confidence interval [CI], 0.01-0.27), surface under the cumulative ranking (SUCRA) = 94.0; DNG (OR, 0.11; 95% CI, 0.04-0.32), SUCRA = 69.7; GnRHa plus OCP (OR, 0.12; 95% CI, 0.02-0.64), SUCRA = 63.4; GnRHa plus LNGIUS (OR, 0.13; 95% CI, 0.03-0.66), SUCRA = 59.4; and OCP (OR, 0.21; 95% CI, 0.13-0.36), SUCRA = 43.6. The effectiveness of GnRHa (OR, 0.47; 95% CI, 0.12-1.89), SUCRA = 17.3 was not significantly different from that of controls. CONCLUSION: In network meta-analysis, combined postoperative adjuvant therapy and longer maintenance hormone treatment are better than a single agent in preventing postoperative endometrioma recurrence. GnRHa plus DNG maintenance treatment might be the most effective intervention. Large-scale RCTs of these agents are still required.
引用
- Chiu CC, Hsu TF, Jiang LY, et al. Maintenance Therapy for Preventing Endometrioma Recurrence after Endometriosis Resection Surgery - A Systematic Review and Network Meta-analysis. J Minim Invasive Gynecol. 2022. PMID: 35123042. doi:10.1016/j.jmig.2021.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。